JOIN US FOR A LIVE SPEAKER PROGRAM
TREATMENT UPDATE:
The First FDA-Approved Treatment for Molluscum Contagiosum
Sponsored by Verrica Pharmaceuticals Inc.
Presented by :
Mercedes Gonzalez, MD
Date :
September 26, 2024
Time :
6:00 pm (America/New_York)
Event Location :

The Capital Grille
2430 E. Sunrise Blvd, , Fort Lauderdale, Florida, 33304

Hosted by: Verrica Pharmaceuticals Inc.
Jazmyne Johnson
(317) 308-8160
jjohnson@verrica.com
Kindly fill the details below to register for the meeting.

First Name :
Last Name :
Designation :
NPI : Click here to find your NPI number
Email Address :
Phone Number :
The most common adverse reactions to YCANTH occurred at the application site, and included blistering, pain, itching, scabbing, reddening, discoloration, dryness, edema (swelling), and erosion of the skin. Contact with the treatment area should be avoided, including oral contact, after treatment. YCANTH is flammable, even after drying.
INDICATION
YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
Scan the QR code or visit this link to see full Prescribing Information for additional information on risks associated with YCANTH.
as